1.Prokaryotic expression, purification and immunogenicity of SARS-CoV-2 omicron variant nucleocapsid protein.
Zewen TU ; Quansheng WANG ; Shiguo LIU ; Haosen LIU ; Chunyan ZENG ; Juanjuan XIE ; Mingzhi LI ; Jingcai LI ; Min WANG ; Shiqi WENG ; Lumei KANG ; Lingbao KONG
Chinese Journal of Cellular and Molecular Immunology 2025;41(8):735-743
Objective The study aims to investigate the immunological functions of the nucleocapsid (N) protein of the novel coronavirus Omicron (BA.1, BA.2) and evaluate the differences among different N proteins of mutant strains in immunogenicity. Methods By aligning sequences, the mutation sites of the Omicron (BA.1, BA.2) N protein relative to prototype strain of the novel coronavirus (Wuhan-Hu-1) were determined. The pET-28a-N-Wuhan-Hu-1 plasmid was used as template to construct pET-28a-BA.1/BA.2-N through single point mutation or homologous recombination. The three kinds of N protein were expressed in prokaryotic system, purified through Ni-NTA affinity chromatography, and then immunized into mice. The titer and reactivity of the polyclonal antibody, as well as the expression level of IL-1β and IFN-γ in mouse spleen cells, were detected using indirect ELISA and Western blot assay. Results The constructed prokaryotic expression plasmids were successfully used to express the Wuhan-Hu-1 N, BA.1 N, and BA.2 N proteins in E.coli BL21(DE3) at 37 DegreesCelsius for 4 hours. The indirect ELISA test showed that the titers of polyclonal antibody prepared by three N proteins were all 1:51 200. All three N proteins can increase the expression of IFN-γ and IL-1β cytokines, but the effect of Omicron N protein in activing two cytokines was more obvious than that of Wuhan-Hu-1 N protein. Conclusion The study obtained three new coronavirus N proteins and polyclonal antibodies, and confirmed that mutations in the amino acid sites of the N protein can affect its immunogenicity. This provides a basis for developing rapid diagnostic methods targeting N protein of different novel coronavirus variants.
Animals
;
Mice
;
SARS-CoV-2/genetics*
;
Coronavirus Nucleocapsid Proteins/immunology*
;
Nucleocapsid Proteins/isolation & purification*
;
COVID-19/immunology*
;
Antibodies, Viral/immunology*
;
Mice, Inbred BALB C
;
Interferon-gamma/metabolism*
;
Interleukin-1beta/metabolism*
;
Female
;
Escherichia coli/metabolism*
;
Mutation
;
Humans
2.A truncated N protein-based ELISA method for the detection of antibodies against porcine deltacoronavirus.
Dongsheng WANG ; Ruiming YU ; Liping ZHANG ; Yingjie BAI ; Xia LIU ; Yonglu WANG ; Xiaohua DU ; Xinsheng LIU
Chinese Journal of Biotechnology 2025;41(7):2760-2773
This study aims to establish an antibody detection method for porcine deltacoronavirus (PDCoV). The recombinant proteins PDCoV-N1 and PDCoV-N2 were expressed via the prokaryotic plasmid pColdII harboring the N gene sequence of the PDCoV strain CH/XJYN/2016. The reactivity and specificity of PDCoV-N1 and PDCoV-N2 with anti-PEDV sera were analyzed after the recombinant proteins were analyzed by SDS-PAGE and purified by the Ni-NTA Superflow Cartridge. Meanwhile, Western blotting and indirect immunofluorescence assay were carried out separately to validate the recombinant proteins PDCoV-N1 and PDCoV-N2. Finally, we established an indirect ELISA method based on the recombinant protein PDCoV-N2 after optimizing the conditions and tested the sensitivity, specificity, and reproducibility of the method. Then, the established method was employed to examine 102 clinical serum samples. The recombinant protein PDCoV-N2 showed low cross-reactivity with anti-PEDV sera. The optimal conditions of the indirect ELISA method based on PDCoV-N2 were as follows: the antigen coating concentration of 1.25 μg/mL and coating at 37 ℃ for 1 h; blocking by BSA overnight at 4 ℃; serum sample dilution at 1:50 and incubation at 37 ℃ for 1 h; secondary antibody dilution at 1:80 000 and incubation at 37 ℃ for 1 h; color development with TMB chromogenic solution at 37 ℃ for 10 min. The S/P value ≥ 0.45, ≤0.38, and between 0.45 and 0.38 indicated that the test sample was positive, negative, and suspicious, respectively. The testing results of the antisera against porcine epidemic diarrhea virus (PEDV), porcine circovirus 2 (PCV2), transmissible gastroenteritis virus (TGEV), foot-and-mouth disease virus (FMDV), and African swine fever virus (ASFV) showed that the S/P values were all less than 0.38. The testing results of the 800-fold diluted anti-PDCoV sera were still positive. The results of the inter- and intra-batch tests showed that the coefficients of variation of this method were less than 10%. Clinical serum sample test results showed the coincidence rate between this method and neutralization test was 94.12%. In this study, an ELISA method for the detection of anti-PDCoV antibodies was successfully established based on the truncated N protein of PDCoV. This method is sensitive, specific, stable, and reproducible, serving as a new method for the clinical diagnosis of PDCoV.
Animals
;
Enzyme-Linked Immunosorbent Assay/methods*
;
Swine
;
Antibodies, Viral/blood*
;
Recombinant Proteins/genetics*
;
Deltacoronavirus/isolation & purification*
;
Coronavirus Infections/virology*
;
Swine Diseases/diagnosis*
;
Coronavirus Nucleocapsid Proteins
;
Sensitivity and Specificity
3.High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors.
Yao ZHAO ; Xiaoyu DU ; Yinkai DUAN ; Xiaoyan PAN ; Yifang SUN ; Tian YOU ; Lin HAN ; Zhenming JIN ; Weijuan SHANG ; Jing YU ; Hangtian GUO ; Qianying LIU ; Yan WU ; Chao PENG ; Jun WANG ; Chenghao ZHU ; Xiuna YANG ; Kailin YANG ; Ying LEI ; Luke W GUDDAT ; Wenqing XU ; Gengfu XIAO ; Lei SUN ; Leike ZHANG ; Zihe RAO ; Haitao YANG
Protein & Cell 2021;12(11):877-888
A new coronavirus (SARS-CoV-2) has been identified as the etiologic agent for the COVID-19 outbreak. Currently, effective treatment options remain very limited for this disease; therefore, there is an urgent need to identify new anti-COVID-19 agents. In this study, we screened over 6,000 compounds that included approved drugs, drug candidates in clinical trials, and pharmacologically active compounds to identify leads that target the SARS-CoV-2 papain-like protease (PLpro). Together with main protease (M
Antiviral Agents/therapeutic use*
;
Binding Sites
;
COVID-19/virology*
;
Coronavirus Papain-Like Proteases/metabolism*
;
Crystallography, X-Ray
;
Drug Evaluation, Preclinical
;
Drug Repositioning
;
High-Throughput Screening Assays/methods*
;
Humans
;
Imidazoles/therapeutic use*
;
Inhibitory Concentration 50
;
Molecular Dynamics Simulation
;
Mutagenesis, Site-Directed
;
Naphthoquinones/therapeutic use*
;
Protease Inhibitors/therapeutic use*
;
Protein Structure, Tertiary
;
Recombinant Proteins/isolation & purification*
;
SARS-CoV-2/isolation & purification*
4.Clinical characteristics of 16 patients with fecal severe acute respiratory syndrome coronavirus 2 nucleic acid-positive.
Yan ZHOU ; Zhiquan XIAO ; Dong CHEN ; Jing GUAN ; Zhiguo ZHOU ; Huirong ZHANG ; Huanfa ZHOU
Journal of Central South University(Medical Sciences) 2020;45(5):560-564
OBJECTIVES:
To analyze the clinical characteristics of fecal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid-positive in patients with coronavirus dasease 2019 (COVID-19) and to provide a scientific basis for the prevention and control of this disease.
METHODS:
The clinical data of 16 patients with fecal SARS-CoV-2 nucleic acid positive, who hospitalized in the North Branch of the First Hospital of Changsha (Changsha Public Health Rescue Center) from January to February 2020, were retrospectively analyzed. Their clinical manifestations, laboratory data and imaging data were summarized.
RESULTS:
Among the 16 patients, there were 9 males (56.25%) and 7 females (43.75%), the ratio of males to females was 1∶1.29. The age of onset was (43.3±14.6) years. There were 15 patients with contact history of Wuhan, 1 patient with contact history of local patient.Twelve patients were common type (75%), and 4 patients were severe type (25%). Clinical symptoms included fever in 14 patients (87.5%), cough in 12 patients (75%), shortness of breath in 5 patients (31.25%), pharyngalgia in 10 patients (62.5%), fatigue in 7 patients (43.75%), and diarrhea in 4 patients (25%). There were 14 patients (87.5%) with normal or decreased white blood cell count, 11 patients (68.75%) with decreased lymphocyte count, 15 patients (93.75%) with increased erythrocyte sedimentation rate, 13 patients (81.25%) with increased hypersensitivity C-reactive protein, 5 patients (31.25%) with increased procalcitonin, and 8 patients (50%) with increased serum ferritin in peripheral blood, and stool routine was basically normal. Compared with the common type, there was significant difference in the white blood cell and lymphocyte counts in the severe type (<0.01); the infection indicators, such as hypersensitivity C-reactive protein and serum ferritin, were significantly increased, with significant difference (all <0.01); but the procalcitonin and erythrocyte sedimentation rate was not significantly different (both >0.05). Chest CT mainly showed patchy shadows and interstitial changes. According to imaging examination, 4 patients (25%) showed unilateral pneumonia and 12 patients (75%) showed bilateral pneumonia.
CONCLUSIONS
The patients have the clinical symptoms of COVID-19, but gastrointestinal symptoms (such as diarrhea) are more common, and the changes of white blood cell count, lymphocyte count, hypersensitivity C-reactive protein, ferritin are more obvious in severe patients.The positivity of fecal nucleic acid suggests the possibility of digestive tract transmission of SARS-CoV-2, and fecal nucleic acid testing can be used as a routine testing method in clinical practice.
Adult
;
Betacoronavirus
;
isolation & purification
;
C-Reactive Protein
;
analysis
;
China
;
Coronavirus Infections
;
diagnosis
;
physiopathology
;
Diarrhea
;
virology
;
Feces
;
virology
;
Female
;
Ferritins
;
analysis
;
Humans
;
Leukocyte Count
;
Male
;
Middle Aged
;
Pandemics
;
Pneumonia, Viral
;
diagnosis
;
physiopathology
;
Retrospective Studies
5.Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study.
Li-Li REN ; Ye-Ming WANG ; Zhi-Qiang WU ; Zi-Chun XIANG ; Li GUO ; Teng XU ; Yong-Zhong JIANG ; Yan XIONG ; Yong-Jun LI ; Xing-Wang LI ; Hui LI ; Guo-Hui FAN ; Xiao-Ying GU ; Yan XIAO ; Hong GAO ; Jiu-Yang XU ; Fan YANG ; Xin-Ming WANG ; Chao WU ; Lan CHEN ; Yi-Wei LIU ; Bo LIU ; Jian YANG ; Xiao-Rui WANG ; Jie DONG ; Li LI ; Chao-Lin HUANG ; Jian-Ping ZHAO ; Yi HU ; Zhen-Shun CHENG ; Lin-Lin LIU ; Zhao-Hui QIAN ; Chuan QIN ; Qi JIN ; Bin CAO ; Jian-Wei WANG
Chinese Medical Journal 2020;133(9):1015-1024
BACKGROUND:
Human infections with zoonotic coronaviruses (CoVs), including severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV, have raised great public health concern globally. Here, we report a novel bat-origin CoV causing severe and fatal pneumonia in humans.
METHODS:
We collected clinical data and bronchoalveolar lavage (BAL) specimens from five patients with severe pneumonia from Wuhan Jinyintan Hospital, Hubei province, China. Nucleic acids of the BAL were extracted and subjected to next-generation sequencing. Virus isolation was carried out, and maximum-likelihood phylogenetic trees were constructed.
RESULTS:
Five patients hospitalized from December 18 to December 29, 2019 presented with fever, cough, and dyspnea accompanied by complications of acute respiratory distress syndrome. Chest radiography revealed diffuse opacities and consolidation. One of these patients died. Sequence results revealed the presence of a previously unknown β-CoV strain in all five patients, with 99.8% to 99.9% nucleotide identities among the isolates. These isolates showed 79.0% nucleotide identity with the sequence of SARS-CoV (GenBank NC_004718) and 51.8% identity with the sequence of MERS-CoV (GenBank NC_019843). The virus is phylogenetically closest to a bat SARS-like CoV (SL-ZC45, GenBank MG772933) with 87.6% to 87.7% nucleotide identity, but is in a separate clade. Moreover, these viruses have a single intact open reading frame gene 8, as a further indicator of bat-origin CoVs. However, the amino acid sequence of the tentative receptor-binding domain resembles that of SARS-CoV, indicating that these viruses might use the same receptor.
CONCLUSION
A novel bat-borne CoV was identified that is associated with severe and fatal respiratory disease in humans.
Adult
;
Aged
;
Betacoronavirus
;
genetics
;
isolation & purification
;
Coronavirus Infections
;
diagnostic imaging
;
therapy
;
virology
;
Female
;
Humans
;
Male
;
Middle Aged
;
Pandemics
;
Pneumonia, Viral
;
diagnostic imaging
;
therapy
;
virology
;
Tomography, X-Ray
;
Treatment Outcome
6.Follow-up testing of viral nucleic acid in discharged patients with moderate type of COVID-19.
Youjiang LI ; Yingying HU ; Xiaodong ZHANG ; Yuanyuan YU ; Bin LI ; Jianguo WU ; Yingping WU ; Xiaoping XIA ; Jian XU
Journal of Zhejiang University. Medical sciences 2020;49(2):270-274
OBJECTIVE:
To investigate the clinical outcome of patients with moderate type of coronavirus disease 2019 (COVID-19) after discharge by retesting viral nucleic acid.
METHODS:
Seven patients with moderate COVID-19 met the discharge criteria enacted by National Health Commission were quarantined in hospital for 7 days, then continuously quarantined at home for 4 weeks after discharged. During the quarantined period, the symptoms and signs were documented, and sputum or nasal swab and feces samples were collected to test SARS-CoV-2 nucleic acid by RT-PCR method.
RESULTS:
There was no symptoms and signs during the quarantine period in all 7 patients. However, respiratory swabs from 3 patients were confirmed positive of SARS-CoV-2 nucleic acid at 5 to 7 days after they met the discharge criteria.
CONCLUSIONS
There is a relatively high incidence of positive viral nucleic acid in patients met the discharge criteria, and it is suggested that patients met the current discharge criteria should be quarantined in hospital for another 7 days and the follow-up viral testing is necessary.
Betacoronavirus
;
isolation & purification
;
Coronavirus Infections
;
diagnosis
;
Feces
;
chemistry
;
virology
;
Follow-Up Studies
;
Humans
;
Pandemics
;
Patient Discharge
;
statistics & numerical data
;
Pneumonia, Viral
;
diagnosis
;
Quarantine
;
statistics & numerical data
;
RNA, Viral
;
analysis
;
Reverse Transcriptase Polymerase Chain Reaction
;
Time Factors
7.Analysis of medication characteristics of traditional Chinese medicine in treating COVID-19 based on data mining.
Tiantian FAN ; Yongcan CHEN ; Yu BAI ; Fengqi MA ; Hengcang WANG ; Yiping YANG ; Jinxu CHEN ; Yuqi LIN
Journal of Zhejiang University. Medical sciences 2020;49(2):260-269
OBJECTIVE:
To analysis the medication characteristics of the prescriptions issued via open channel by the National and Provincial Health Committee and the State Administration of Traditional Chinese Medicine in treating coronavirus disease 2019 (COVID-19).
METHODS:
We collected the data of traditional Chinese medicine related to treatment plans published by the National and Provincial Health Committee and the State Administration of Traditional Chinese Medicine from the start of COVID-19 outbreak to February 19, 2020. The frequency analysis, cluster analysis and association analysis were performed.
RESULTS:
The study collected 4 national and 34 regional prevention and treatment plans, 578 items, 84 traditional Chinese formulations, 60 Chinese patent medicines, and 230 Chinese herbs. The high frequently used herbs were , and . The commonly used traditional formulations included decoction, powder, and decoction. The Chinese patent drugs included pill, injection, and capsule. The most common paired medications were and and Two core combinations and one novel formula were discovered in the study.
CONCLUSIONS
powder and decoction are the basic formulations for syndrome of COVID-19. In addition, decoction, powder, decoction and decoction are the basic formulations for syndrome of COVID-19. The main medication characteristics are clearing heat, entilating lung, removing toxicity and removing turbidity. It shows that removing toxicity and eliminating evil are the prescription thought in treating epidemic disease of traditional Chinese medicine.
Betacoronavirus
;
isolation & purification
;
Coronavirus Infections
;
therapy
;
Data Mining
;
Drugs, Chinese Herbal
;
chemistry
;
therapeutic use
;
Humans
;
Medicine, Chinese Traditional
;
Pandemics
;
Pneumonia, Viral
;
therapy
8.Anesthesia management in cesarean section for patient with COVID-19: a case report.
Xianhui KANG ; Rong ZHANG ; Huiliang HE ; Yongxing YAO ; Yueying ZHENG ; Xiaohong WEN ; Shengmei ZHU
Journal of Zhejiang University. Medical sciences 2020;49(2):249-252
Since the coronavirus disease 2019 (COVID-19) affects the cardio-pulmonary function of pregnant women, the anesthetic management and protection of medical staff in the cesarean section is significantly different from that in ordinary surgical operation. This paper reports a case of cesarean section for a woman with COVID-19, which was successfully performed in the First Affiliated Hospital of Zhejiang University School of Medicine on February 8, 2020. Anesthetic management, protection of medical staff and psychological intervention for the pregnant woman during the operation were discussed. Importance has been attached to the preoperative evaluation of pregnant women with COVID-19 and the implementation of anesthesia plan. For moderate patients, intraspinal anesthesia is preferred in cesarean section, and try to reduce its influence in respiration and circulation in both maternal and infant; general anesthesia with endotracheal intubation should be adopted for severe or critically ill patients. Ensure the safety of medical environment, and anesthetists should carry out level-Ⅲ standard protection. Special attention and support should be paid to maternal psychology: fully explanation before operation to reduce anxiety; relieve the discomfort during operation, so as to reduce tension; avoid the bad mood due to pain after operation.
Anesthesia
;
Betacoronavirus
;
isolation & purification
;
Cesarean Section
;
methods
;
Coronavirus Infections
;
complications
;
Female
;
Humans
;
Infant
;
Injections, Spinal
;
Pandemics
;
Pneumonia, Viral
;
complications
;
Pregnancy
9.Management of a colon cancer patient complicated with COVID-19.
Ziqi YE ; Yun HONG ; Xiuhua WU ; Dongsheng HONG ; Yanfang ZHANG ; Xihao DONG ; Yuefeng RAO ; Xiaoyang LU
Journal of Zhejiang University. Medical sciences 2020;49(2):245-248
OBJECTIVE:
To explore the feasibility of radical resection for cancer patients complicated with coronavirus disease 2019 (COVID-19).
METHODS:
The management and clinical outcome of a sigmoid cancer patient with COVID-19 were analyzed.
RESULTS:
The inflammation indicators and fever of this patient were effectively controlled and the lung lesions remained stable after active anti-viral treatment, then the radical colorectomy was performed after the viral negative conversion for twice.
CONCLUSIONS
The case indicates that radical resection can be performed in SARS-CoV-2 patients with twice-negative SARS-CoV-2 nucleic acid testing results.
Betacoronavirus
;
isolation & purification
;
Colonic Neoplasms
;
complications
;
surgery
;
Coronavirus Infections
;
complications
;
therapy
;
Disease Management
;
Humans
;
Pandemics
;
Pneumonia, Viral
;
complications
;
therapy
;
Treatment Outcome
10.Pregnant women complicated with COVID-19: a clinical analysis of 3 cases.
Xu CHEN ; Yang LI ; Jinxi WANG ; Hongliu CAI ; Hongcui CAO ; Jifang SHENG
Journal of Zhejiang University. Medical sciences 2020;49(2):240-244
OBJECTIVE:
To analyze the clinical characteristics and pregnancy outcomes of pregnant women complicated with coronavirus disease 2019 (COVID-19).
METHODS:
The clinical data of 3 pregnant women with COVID-19 admitted to the First Affiliated Hospital of Zhejiang University School of Medicine from January 19 to February 10, 2020 were retrospectively analyzed.
RESULTS:
There was one case in the first-trimester pregnancy (case 1), one in the second-trimester pregnancy (case 2) and one in third-trimester pregnancy (case 3). Cough, fever, fatigue, lung imaging changes were the main manifestations. The white cell count, lymphocyte percentage had no significantly changes in case 1 and case 3, while the levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), IL-6 and IL-10 elevated. The lymphocyte count and lymphocyte percentage decreased and the inflammatory indicators significantly increased in case 2. All patients were treated with antiviral, antitussive, oxygen inhalation; case 3 received glucocorticoids, case 2 with severe illness received glucocorticoids and additionally gamma globulin. All three cases were cured and discharged. Case 1 with early pregnancy chose to terminate pregnancy after discharge; case 2 chose to continue pregnancy without obstetric complications; and case 3 had cesarean section delivery due to abnormal fetal heart monitoring.
CONCLUSIONS
The report shows that COVID-19 in pregnancy women could be cured with active treatment, and the maternal and fetal outcomes can be satisfactory.
Antiviral Agents
;
therapeutic use
;
Betacoronavirus
;
isolation & purification
;
Cesarean Section
;
Coronavirus Infections
;
complications
;
drug therapy
;
Female
;
Glucocorticoids
;
therapeutic use
;
Humans
;
Oxygen
;
therapeutic use
;
Pandemics
;
Pneumonia, Viral
;
complications
;
drug therapy
;
Pregnancy
;
Pregnancy Complications, Infectious
;
drug therapy
;
pathology
;
Pregnancy Outcome
;
Retrospective Studies
;
Treatment Outcome
;
gamma-Globulins
;
therapeutic use

Result Analysis
Print
Save
E-mail